Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844)

Ophthalmology. 2017 Oct;124(10):e74-e75. doi: 10.1016/j.ophtha.2017.05.007.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors
  • Bevacizumab*
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Intravitreal Injections
  • Retinopathy of Prematurity*
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Bevacizumab